US FDA Panel Rejects Trelegy Ellipta COPD Mortality Claim; Worries Include Potential Overuse

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
Panel votes 14-1 against mortality benefit labeling for Trelegy Ellipta.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers